Objectives:
In both bone and dentin, DMP1 is processed into N-terminal and C-terminal
fragments at four cleavage sites and the N-terminal fragment contains a glycosaminoglycan
(GAG) chain, designated DMP1-PG. To begin to determine if proteolytic processing
and glycosylation are essential for the function of DMP1, we mutated one cleavage
site (Asp213 to Ala, designated the D213A mutation) and the GAG
chain attachment site (Ser105 changed to Gly, referred to as S105G
mutation). Methods: Mutations were performed on normal control murine
DMP1 cDNA. The cDNA fragments with desired mutations were subcloned into the
pcDNA3 expression vector containing a CMV promoter. Expression constructs with
mutated DMP1 cDNA or with control DMP1 cDNA were transfected into HEK-293
cells. DMP1 and its secreted fragments were analyzed by SDS-PAGE, Stains-All
staining and Western immunoblotting using antibodies specific to the N-terminal
and C-terminal regions of mouse DMP1. Results: In the medium of HEK-293
cells transfected with the pcDNA3 vector containing the control murine DMP1 cDNA,
full-length DMP1 as well as N-terminal and C-terminal fragments were detected.
In the cells transfected with the vector containing the D213A mutation, little
detectable DMP1 N-terminal and C-terminal fragments were observed whereas
increased secretion of intact, full-length DMP1 was clearly evident. In the
cells transfected with the vector containing S105G mutation, DMP1-PG was
completely absent. Conclusions: 1).The finding that mutation of Asp213
almost completely blocks the proteolytic processing of mouse DMP1 suggests that
this residue is the key site for initiation of the cleavage cascade for DMP1
processing. 2). The observation that the S105G mutation completely prevents the
formation of the GAG-containing form of DMP1 further confirms our previous
observations that murine DMP1 contains a single GAG chain at S105.
Characterization of these processing and glycosylation sites will help
determine DMP1 functions. Supported by NIH grant DE005092 (CQ).